---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-24-000061"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T10:30:50.206843+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics licenses certepetide to Kuva Labs for solid tumor imaging

## Summary
- Upfront cash license fee of $1.0M payable over 12 months in four installments.
- Development milestones up to $1.5M; commercial milestones up to $17.5M; 5% royalty on net sales.
- Kuva assumes full R&D and commercialization costs; Lisata to supply certepetide for clinical and commercial use.
- Partnership combines Lisata's certepetide with Kuva's NanoMark imaging technology for solid tumors.
- Agreement effective November 30, 2024; Kuva may terminate on 60-day notice.

## SEC filing metadata
- accession: 0000320017-24-000061
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001724000061/0000320017-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001724000061/clbs-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-24-000061
- JSON: https://secwatch.observer/filing/0000320017-24-000061.json
- Plain text: https://secwatch.observer/filing/0000320017-24-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.